TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
Brief description of study
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine any changes in your health or side effects occurring within 24 hours following treatment with TEGSEDI.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
hATTR-PN
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female Age 18 or older Diagnosis of hATTR-PN
Updated on
09 Mar 2024.
Study ID: TEG4004
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
